# Core B

> **NIH NIH P01** · UNIVERSITY OF FLORIDA · 2022 · $328,124

## Abstract

CORE SUMMARY/ABSTRACT
Core B, commonly considered by investigators of this P01 as the “Laboratory Core”, has…and is proposed to
continue to provide three separate but highly integrated functions, each representing a critical element to the
P01's Projects and ultimately, their collective success. These constituents include: 1) Provide patient
consenting, sample collection and access to study subject samples essential for all Projects. Here, the Core
will oversee study subject identification, provide appropriate patient consenting, and arrange for sample
collection. 2) Standardize sample processing, perform genotyping and clinical laboratory testing, distribute
samples to investigators, and offer reliable, secure, high quality specimen storage. Here, Core B will ensure
that high quality specimens are obtained through adherence to good laboratory practice (GLP) procedures,
computerized sample tracking, biobanking best practices, storage, as well as emergency response planning by
trained staff. The Core will routinely store samples collected as part of the Program, including serum, plasma,
peripheral blood mononuclear cells (PBMC), DNA, and RNA (as necessary for the needs of the specific
Projects). The samples will be securely managed using web-based software (Diabase and Sharepoint) that
together, tracks and provides investigators knowledge regarding study subject demographics, collection and
annotation of specimens, specimen processing methods, specimen availability, storage, quality assurance and
distribution of samples. With this, Core B will provide Projects 1, 2, & 3 with uniformly processed samples in
order to optimize multivariate analysis of data across the Program. A second activity for this Core within this
aim involves performance of a series of immunologic, metabolic, and genetic based laboratory assays.
Specifically, as a routine analysis for all study subjects, the Core will provide: A) immunologic testing for T1D
autoantibodies, measurement of type 1 interferon levels (HEK-Blue IFN reporter cells), CBC, and extensive
human immunophenotyping (HIP) by flow cytometry; B) metabolic analysis of glucose and HbA1C levels; and
C) genetic typing involving the highly innovative Axiom human genotyping array (termed, UFDIchip) analysis
that will include HLA typing as well as single nucleotide polymorphism (SNPs) based information relevant to
the various Projects in this P01. Importantly, these assays will be performed following clinical laboratory
standards; an effectiveness that will be determined by participation in national/international programs to assure
QA/QC. For example, the Core's performance in the International Diabetes Autoantibody Standardization
Program (IASP) routinely scores with high sensitivity/specificity. 3) Core B will also provide database support
for collection and storage of regulatory documents, patient demographic and clinical information, and research
data to facilitate investigator access/data analysis within and acros...

## Key facts

- **NIH application ID:** 10412998
- **Project number:** 5P01AI042288-24
- **Recipient organization:** UNIVERSITY OF FLORIDA
- **Principal Investigator:** Patrick Concannon
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $328,124
- **Award type:** 5
- **Project period:** 1997-09-30 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10412998

## Citation

> US National Institutes of Health, RePORTER application 10412998, Core B (5P01AI042288-24). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10412998. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*